June 17 (UPI) — Shares in Hong Kong-based Regencell Bioscience Holdings practically quadrupled in worth amid a 38-to-1 inventory cut up regardless of the agency reporting no revenues.
The inventory cut up triggered a 280% share worth improve on Monday, CNBC reported, and continued a 58,000% improve in its worth in 2025, with a closing value of $78 per share on the NASDAQ buying and selling platform on Tuesday.
The inventory reached a excessive of $81.23 throughout morning buying and selling and slumped barely to $75.47 throughout Tuesday’s after-hours buying and selling.
The inventory is rated as a “purchase” on the TipRanks web site after Regencell officers on June 2 introduced the inventory cut up to enhance its liquidity and worth for shareholders.
The inventory cut up gave traders 37 shares for every share held on June 12. The shares started buying and selling on a split-adjusted foundation on Monday, in accordance with Seeking Alpha.
The agency has no reported income however says it’s growing a Chinese language natural remedy for childhood consideration deficit hyperactivity dysfunction and autism.
The agency was established in 2014 and has been traded on NASDAQ beneath the RGC image since 202.
It had a market capitalization of $29.7 billion on the finish of buying and selling on Monday.
The market capitalization rose one other 25% on Tuesday, with a complete worth of $36 billion.
The inventory traded for pennies per share final yr however now has a better market worth than extremely acknowledged companies, together with Kraft Heinz, Lululemon and eBay, in accordance with CNBC.
A part of the elevated investor curiosity is because of Well being and Human Providers Secretary Robert Kennedy Jr. elevating consciousness of different medicines.
Regencell Chief Government Officer Yat-Gai Au controls greater than 86% of the corporate’s excellent shares, in accordance with FactSet.
Little data is on the market concerning the potential effectiveness of the corporate’s claims concerning its three conventional Chinese language drugs formulation which might be imagined to deal with gentle to extreme types of ADHD and autism with pure natural medicines in liquid kind.
Firm officers in October reported no generated income and no regulatory approvals for its three liquid medicines.
They reported internet losses of $6.06 million in 2023 and $4.36 million in 2024.
A Regencell affected person case research in late 2023 stated 28 sufferers had been handled over three months throughout a second trial, which confirmed enhancements in ADHD and autism.
A dozen sufferers participated in a 2021 research to deal with COVID-19, which indicated enchancment of their signs.
